BIIB Share Price

Open 290.00 Change Price %
High 291.90 1 Day 10.03 3.62
Low 285.90 1 Week 14.95 5.50
Close 286.89 1 Month 12.07 4.39
Volume 3123660 1 Year 5.19 1.84
52 Week High 333.65
52 Week Low 223.02
BIIB Important Levels
Resistance 2 292.45
Resistance 1 290.16
Pivot 288.23
Support 1 283.62
Support 2 281.33
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
AKRX 33.09 1.13%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
WRES 0.09 28.57%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 100.00%
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
CLNT 4.50 30.81%
CALI 3.45 29.21%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Biogen Idec Inc. (NASDAQ: BIIB)

BIIB Technical Analysis 3
As on 25th Apr 2017 BIIB Share Price closed @ 286.89 and we RECOMMEND Buy for LONG-TERM with Stoploss of 286.18 & Buy for SHORT-TERM with Stoploss of 279.82 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIIB Target for April
1st Target up-side 289.91
2nd Target up-side 301.47
3rd Target up-side 313.03
1st Target down-side 256.93
2nd Target down-side 245.37
3rd Target down-side 233.81
BIIB Other Details
Segment EQ
Market Capital 33194547200.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biogenidec.com
BIIB Address
BIIB
225 Binney Street
Cambridge, MA 02142
United States
Phone: 781-464-2000
BIIB Latest News
Biogen Inc (BIIB) Stock Rating Reaffirmed by Mizuho   The Cerbat Gem   - 19th Apr 17
For $300M, Biogen Beefs Up Its Alzheimer's Attack   Seeking Alpha   - 19th Apr 17
Commit To Buy Biogen At $140, Earn 2.6% Using Options   Nasdaq   - 18th Apr 17
Shares in Review: Biogen Inc. (NASDAQ:BIIB)   Rives Journal   - 18th Apr 17
Few Things investors Didn't Know About: Biogen Inc. (BIIB), Taylor Morrison ...   StockNewsJournal   - 18th Apr 17
Smart Money Still Has Faith in Biogen Inc. (NASDAQ:BIIB)   Midway Monitor   - 18th Apr 17
Biogen licenses experimental drug with Alzheimer's potential   The Boston Globe   - 13th Apr 17
Biogen's Valuation Is Compelling   Seeking Alpha   - 04th Apr 17
Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding ...   GlobeNewswire (press release)   - 01st Apr 17
The Hudock Capital Group LLC Holds Stake in Biogen Inc. (BIIB)   Petro Global News 24   - 31st Jan 17
Interactive Technical Analysis Chart Biogen Idec Inc. ( BIIB NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biogen Idec Inc.
BIIB Business Profile
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.